New antibody therapy shows promise for Hard-to-Treat multiple myeloma

NCT ID NCT03145181

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it works and how the body handles it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU Tours Hopital Bretonneau

    Tours, 37044, France

  • City of Hope

    Duarte, California, 91010, United States

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Haematology Centre, R 51

    Stockholm, SE-141 86, Sweden

  • Hosp Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, 08916, Spain

  • Hospices Civils de Lyon HCL

    Lyon, 69002, France

  • Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects

    New York, New York, 10029, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • VU Medisch Centrum

    Amsterdam, 1081 HV, Netherlands